U.S. Menopause Market Size, Share & Trends Analysis Report 2025-2033: Competitive Analysis Of Pfizer, Novo Nordisk, Therapeuticsmd, Bayer, Abbvie, Pure Encapsulations, PADAGIS

(MENAFN- GlobeNewsWire - Nasdaq) The U.S. menopause market presents key opportunities in increasing demands for menopause products due to a growing menopausal population, a rise in awareness, and preferences for natural remedies. Innovative hormone-free therapies and telemedicine services are driving market growth, offering diverse product development and segmentation avenues.

Dublin, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The "U.S. Menopause Market Size, Share & Trends Analysis Report by Type (Hormonal, Non-Hormonal, and Dietary Supplements), by Country (West, South, Midwest), and Segment Forecasts, 2025-2033" report has been added to ResearchAndMarkets's offering.
The U.S. menopause market size was estimated at USD 5.56 billion in 2024 and is projected to reach USD 8.58 billion by 2033, growing at a CAGR of 5.0% from 2025 to 2033.

The increasing number of women who are reaching menopause age and the rise in awareness and education and its related symptoms are resulting in a growing demand for related products, services, and treatments. According to the report published by the National Library of Medicine in 2023, approximately 1.3 million women experience menopause each year, typically between the age group of 45 to 55 in the U.S. Moreover, the increasing preference for natural and organic menopause remedies and the availability of innovative products and technologies in the market, such as hormone-free therapies and telemedicine services, are also contributing to the growth of the market in the U.S.

In addition, as per the Society for Women's health Research, as the millennial population is aging, the country has around 6,000 women are expected to enter menopause each day in the U.S. A survey conducted by AARP, a U.S.-based nonprofit organization, in January 2024, revealed that approximately 90% of women aged 35 and older experience menopausal symptoms that impact their daily lives and work activities. According to the World Health Organization (WHO), menopause typically begins between the ages of 45 to 56 years. Wherein there is a small proportion of women, approximately 5%, who experience it early, naturally which occurs between the ages of 40 and 45 years old.

Furthermore, there is a rare condition known as primary ovarian insufficiency, in which only 1% of women undergo a complete stop of menstruation before the age of 40 due to permanent ovarian failure. Research from the National Library of Medicine indicates that women from certain ethnic backgrounds experience premature and early menopause more frequently than their counterparts from different communities. The incidence of premature menopause is 1.4% for Black and Hispanic women, while it is only 1% for White women.

Why should you buy this report?

• Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
• Competitive Landscape: Explore the market presence of key players.
• Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
• Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

• Market intelligence to enable effective decision-making
• Market estimates and forecasts from 2018 to 2030
• Growth opportunities and trend analyses
• Segmental and regional revenue forecasts for market assessment
• Competition strategy and market share analysis
• Product innovation listings for you to stay ahead of the curve
• COVID-19's impact and how to sustain in these fast-evolving markets

Companies Featured

• Pfizer Inc.
• Novo Nordisk A/S
• TherapeuticsMD, Inc.
• Bayer AG
• AbbVie, Inc.
• Pure Encapsulations, LLC.
• PADAGIS LLC

Key Attributes:

Report Attribute	Details
No. of Pages	100
Forecast Period	2024 - 2033
Estimated Market Value (USD) in 2024	$5.56 Billion
Forecasted Market Value (USD) by 2033	$8.58 Billion
Compound Annual Growth Rate	5.0%
Regions Covered	United States

Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segmental Snapshot
2.3. Competitive Insights Snapshot
Chapter 3. Market Variables, Trends, and Scope
3.1. Market Lineage
3.1.1. Parent Market Analysis
3.1.2. Ancillary Market Analysis
3.2. U.S. Menopause Market- Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. COVID-19 Impact Analysis
3.4. Regulatory & Reimbursement Scenario
3.5. Business Environmental Tools Analysis: U.S. Menopause Market
3.5.1. Porter's Five Forces Analysis
3.5.2. PESTLE Analysis
Chapter 4. U.S. Menopause Market: Type Estimates & Trend Analysis
4.1. U.S. Menopause Market, by Type: Key Takeaways
4.2. U.S. Menopause Market: Type Movement & Market Share Analysis, 2024 & 2033
4.3. Hormonal
4.3.1. Hormonal Market Estimates and Forecasts, 2021-2033 (USD Billion)
4.4. Non-Hormonal
4.5. Dietary Supplements
Chapter 5. U.S. Menopause Market: Country Estimates & Trend Analysis
5.1. U.S. Menopause Market, by Regional: Key Takeaways
5.2. U.S. Menopause Market: Regional Movement & Market Share Analysis, 2024 & 2033
5.3. West
5.3.1. West Menopause Market Estimates and Forecasts, 2021-2033 (USD Billion)
5.4. Southeast
5.5. Southwest
5.6. Midwest
5.7. Northeast
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Company Market Position Analysis
6.3. Strategy Mapping
6.4. Company Profiles
6.4.1. Overview
6.4.2. Financial Performance
6.4.3. Product Benchmarking
6.4.4. Strategic Initiatives
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• U.S. Menopause Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN23092025004107003653ID1110098202